Mammary Cell News Volume 7.37 | Sep 24 2015

Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology
Scientists report the application of RNA nanotechnology for specific and efficient delivery of anti-microRNA (miR)-21 to block the growth of triple negative breast cancer in orthotopic mouse models. [ACS Nano]
Full Article | Graphical Abstract

Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer
Src kinase blockade with the small molecule inhibitor saracatinib prevented the disorganized 3D growth of estrogen receptor-negative (ER⁻) mammary epithelial cells in vitro and delayed the development of pre-malignant lesions and tumors in vivo in mouse models developing HER2⁺ and ER⁻ mammary tumors, extending tumor-free and overall survival. [Cancer Res] Abstract

LRIG1 Opposes Epithelial-to-Mesenchymal Transition and Inhibits Invasion of Basal-Like Breast Cancer Cells
Researchers demonstrated that LRIG1 (leucine-rich repeat and immunoglobulin-like domain containing) is downregulated during epithelial-to-mesenchymal transition (EMT) of human mammary epithelial cells, suggesting that LRIG1 expression may represent a barrier to EMT. [Oncogene] Abstract

Loss of the Tumor Suppressor Spinophilin (PPP1R9B) Increases the Cancer Stem Cell Population in Breast Tumors
The authors explored the mechanism of how spinophilin downregulation contributes to the malignant phenotype and poor prognosis in breast tumors and found an increase in the stemness phenotype. [Oncogene] Abstract

Translational Control of PML Contributes to TNFα-Induced Apoptosis of MCF7 Breast Cancer Cells and Decreased Angiogenesis in HUVECs
Researchers uncovered a novel mechanism of promyelocytic leukemia (PML) gene regulation in which the p38 MAPK and its downstream kinase MAP kinase-activated protein kinase 1 mediate tumor necrosis factor-α (TNFα)-induced PML protein accumulation and PML nuclear body formation. [Cell Death Dis] Full Article

Wogonoside Inhibits Angiogenesis in Breast Cancer via Suppressing Wnt/β-Catenin Pathway
Researchers investigated the inhibitory effect of wogonoside on angiogenesis in breast cancer and its underlying mechanisms. They found it inhibits angiogenesis induced by the conditioned media from MCF-7 cells in vitro and in vivo by migration, tube formation, rat aortic ring, and chicken chorioallantoic membrane assay. [Mol Carcinog] Abstract

Liganded ERα Stimulates the E3 Ubiquitin Ligase Activity of UBE3C to Facilitate Cell Proliferation
Investigators demonstrated a novel function of estrogen receptor alpha (ERα) during mitosis that facilitates estrogen-dependent cell proliferation. An E3 ubiquitin ligase, UBE3C, was identified in an ERα complex from estrogen-treated MCF-7 breast cancer cells arrested at mitosis. [Mol Endocrinol] Abstract | Full Article

Cadmium Promotes the Proliferation of Triple-Negative Breast Cancer Cells through EGFR-Mediated Cell Cycle Regulation
The authors examined cadmium-mediated growth of non-metastatic human breast cancer derived cells that lack receptors for estrogen, progesterone, and HER2. [Toxicol Appl Pharmacol] Abstract

Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids
Scientists analyzed the impact of 3D spatial organization of HER2-overexpressing breast cancer cells on the response to Trastuzumab. They cultured human mammary adenocarcinoma cell lines as spheroids with the hanging drop method and they observed a gradient of proliferating, quiescent, hypoxic, apoptotic and autophagic cells towards the inner core. [PLoS One] Full Article

CLINICAL RESEARCH

Phase I and Pharmacological Trial of Lapatinib in Combination with Gemcitabine in Patients with Advanced Breast Cancer
Female patients with advanced breast cancer were given lapatinib once daily in 28-day cycles with gemcitabine administered on day 1, 8 and 15. [Invest New Drugs] Full Article

Final Overall Survival Analysis of a Phase II Trial Evaluating Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer
Lapatinib plus capecitabine is approved as treatment for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer, who have progressed on prior trastuzumab in the metastatic setting. Researchers assessed the final overall survival in this study at 40 months post-randomization. [Breast] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

From our sponsor:
Modify hPSC genomes and enhance the physiological relevance of your research. Watch the webinar now.

Susan G. Komen^® 2015 Breast Cancer Research Funding Targets Early-Career Investigators, New Therapies, Health Inequities, and Metastatic Disease
Susan G. Komen, the world’s largest nonprofit funder of breast cancer research, announced new grants to 124 researchers in 25 states and eight countries internationally, with about half of the grants targeted to early-career researchers squeezed by stagnation in federal research dollars. [Susan G. Komen] Press Release

UCSF Receives $5 Million to Integrate Data From Cancer Research Models
UC San Francisco has received a National Cancer Institute grant of $5 million over the next five years to lead a massive effort to integrate the data from all experimental models across all types of cancer. [University of California, San Francisco] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Postdoctoral Fellow – Breast Cancer Research (University Health Network)

Research Scientist – Epithelial Stem Cells (A*STAR)

Postdoctoral Research Associate – Breast Cancer Invasion / Extracellular Matrix / Proteomics / Microscopy (University of Liverpool)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Fellowship – Cancer Biology (Massachusetts General Hospital Cancer Center/Harvard Medical School)

Postdoctoral Research Fellow – Metastatic Breast Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Cancer Biology (National Cancer Institute)

Postdoctoral Position – Cancer Biology (Northwestern University)

Postdoctoral Position – Inflammation & Breast Tumor Metastasis (Stephenson Cancer Center)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.